Auro Vaccines terminates license agreement with Hilleman Laboratories Singapore
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Subscribe To Our Newsletter & Stay Updated